et al.Although many cancers initially respond to cisplatin (CDDP)-based chemotherapy, resistance frequently develops. Insulin-like growth factor-binding protein-3 (IGFBP-3) silencing by promoter methylation is involved in the CDDP-acquired resistance process in non-small cell lung cancer (NSCLC) patients. Our purpose is to design a translational-based profile to predict resistance in NSCLC by studying the role of IGFBP-3 in the phosphatidyl inositol 3-kinase (PI3K) signaling pathway. We have first examined the relationship between IGFBP-3 expression regulated by promoter methylation and activation of the epidermal growth factor receptor (EGFR), insulin-like growth factor-I receptor (IGFIR) and PI3K/AKT pathways in 10 human cancer cell lines...
Cisplatin is a platinum agent used in the treatment of non-small cell lung cancer (NSCLC). Much rema...
The invention relates to a method to predict the response to treatment with radiotherapy combined wi...
<div><p>Acquisition of platinum resistance following first line platinum/taxane therapy is commonly ...
Cisplatin (CDDP) is one of the front-line chemotherapeutic drugs used in the treatment of esophageal...
Cisplatin (CDDP) is one of the front-line chemotherapeutic drugs used in the treatment of esophageal...
Expression of insulin-like growth factor-binding protein-3, which (IGFBP-3) inhibits the proliferati...
<div><p>Most patients treated with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) eventually develop ac...
PURPOSE: The activities of insulin-like growth factors (IGFs) in regulating cell proliferation,diffe...
Most patients treated with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) eventually develop acquired r...
BACKGROUND: IGFBP-3 is a multifunctional protein that inhibits growth and induces apoptosis of cance...
Trabajo presentado al 21th Meeting of the European Association for Cancer Research celebrado en Brus...
Most patients treated with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) eventually develop acquired r...
AbstractBACKGROUND: IGFBP-3 is a multifunctional protein that inhibits growth and induces apoptosis ...
Insulin-like growth factor binding protein 3 (IGFBP3), which is induced by wild-type p53, regulates ...
Aberrant hypermethylation of cancer-related genes has emerged as a promising strategy for the develo...
Cisplatin is a platinum agent used in the treatment of non-small cell lung cancer (NSCLC). Much rema...
The invention relates to a method to predict the response to treatment with radiotherapy combined wi...
<div><p>Acquisition of platinum resistance following first line platinum/taxane therapy is commonly ...
Cisplatin (CDDP) is one of the front-line chemotherapeutic drugs used in the treatment of esophageal...
Cisplatin (CDDP) is one of the front-line chemotherapeutic drugs used in the treatment of esophageal...
Expression of insulin-like growth factor-binding protein-3, which (IGFBP-3) inhibits the proliferati...
<div><p>Most patients treated with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) eventually develop ac...
PURPOSE: The activities of insulin-like growth factors (IGFs) in regulating cell proliferation,diffe...
Most patients treated with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) eventually develop acquired r...
BACKGROUND: IGFBP-3 is a multifunctional protein that inhibits growth and induces apoptosis of cance...
Trabajo presentado al 21th Meeting of the European Association for Cancer Research celebrado en Brus...
Most patients treated with EGFR-tyrosine kinase inhibitors (EGFR-TKIs) eventually develop acquired r...
AbstractBACKGROUND: IGFBP-3 is a multifunctional protein that inhibits growth and induces apoptosis ...
Insulin-like growth factor binding protein 3 (IGFBP3), which is induced by wild-type p53, regulates ...
Aberrant hypermethylation of cancer-related genes has emerged as a promising strategy for the develo...
Cisplatin is a platinum agent used in the treatment of non-small cell lung cancer (NSCLC). Much rema...
The invention relates to a method to predict the response to treatment with radiotherapy combined wi...
<div><p>Acquisition of platinum resistance following first line platinum/taxane therapy is commonly ...